We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+25.95%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$269M
AUM Growth
-$59.3M
(-18%)
Cap. Flow
-$75.4M
Cap. Flow
% of AUM
-28.03%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
84
New
37
Increased
10
Reduced
12
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$20.6M |
| 2 |
Medtronic
MDT
|
+$13.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$8.29M |
| 4 |
Legend Biotech
LEGN
|
+$7.63M |
| 5 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$7.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$17.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$17.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$17M |
| 4 |
ARK Innovation ETF
ARKK
|
+$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.24% |
| 3 | Industrials | 0.21% |
| 4 | Energy | 0.12% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Sarepta Therapeutics
SRPT
$1.65B
| – | – |
-88,961
| Closed | -$12.3M |
|
77
Thermo Fisher Scientific
TMO
$208B
| – | – |
-15,889
| Closed | -$9.16M |
|
|
78
Tandem Diabetes Care
TNDM
$1.39B
| – | – |
-417,448
| Closed | -$17M |
|
|
UNIT
79
Uniti Group
UNIT
$2.41B
| – | – |
-11,370
| Closed | -$40.4K |
|
80
Viking Therapeutics
VKTX
$3.81B
| – | – |
-200,000
| Closed | -$3.33M |
|
|
SWN
81
DELISTED
Southwestern Energy Company
SWN
| – | – |
-10,357
| Closed | -$51.8K |
|
|
ETRN
82
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| – | – |
-10,131
| Closed | -$58.6K |
|
|
ISEE
83
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-106,711
| Closed | -$2.6M |
|
|
RXDX
84
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-28,470
| Closed | -$3.06M |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Tri Locum Partners held 84 positions worth $269M, down 18% from $328M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Tri Locum Partners withdrew a net $75.4M in Q2 2023, closing 25 positions and reducing 12 holdings. Its most notable exit was Abbott, an estimated $17.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials and Industrials.
Against the trend, Tri Locum Partners opened a new position in Johnson & Johnson worth $21.1M.
- Tri Locum Partners's largest Q2 2023 buy was Johnson & Johnson: 127,362 shares worth $21.1M.
- Tri Locum Partners added most to Eli Lilly in Q2 2023, an estimated $4.16M increase.
- Tri Locum Partners's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $17.5M.
- Tri Locum Partners fully exited Abbott in Q2 2023, selling an estimated $17.7M.
- Tri Locum Partners's ten largest holdings make up 56% of its $269M portfolio in Q2 2023.
- Tri Locum Partners opened 37 new positions and closed 25 in Q2 2023.
- Tri Locum Partners's portfolio value fell 18% quarter-over-quarter to $269M.
Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.